

Figure S2. Summarized effect size for Prospective (link to Table 2 Part 1)





Figure S3. Summarized effect size for Subgroup analysis I
(link to Table 2 Part 2)






Figure S5. Summarized effect size for Subgroup analysis III
(link to Table 2 Part 2)




Figure S6. Summarized effect size for Subgroup analysis I
(link to Table 2 Part 3)




Figure S7. Summarized effect size for Subgroup analysis II
(link to Table 2 Part 3)




Figure S8. Summarized effect size for Subgroup analysis III
(link to Table 2 Part 3)




Figure S9. Summarized effect size for PC/CP+AP (link to Table 2 Part 4)




Figure S10. Summarized effect size for PDAC/CP+AP (link to Table 2 Part 4)




Figure S11. Summarized effect size for IPMN (link to Table 2 Part 4)




Figure S12. Summarized effect size for Diabetes (link to Table 2 Part 4)




Figure S13. Summarized effect size for AIP (link to Table 2 Part 4)




Figure S14. Summarized effect size for 37.0U/ml (link to Table 2 Part 5)




Figure S15. Summarized effect size for <37.0U/ml (link to Table 2 Part 5)




Figure S16. Summarized effect size for 37.0-100.0U/ml (link to Table 2 Part 5)




Figure S17. Summarized effect size for >100.0U/ml (link to Table 2 Part 5)




Figure S18. Summarized effect size for Optimum [\(link to Table 2 Part 5\)](#)